Search

Displaying results 4561 - 4570 of 10000 in total
  1. Drug

    RP01

    go.drugbank.com/drugs/DB05751
    Experimental

    It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response. … RP01 is a novel anti-IgE immunotherapy for allergic individuals.

  2. Drug

    Pascolizumab

    go.drugbank.com/drugs/DB06560
    Investigational

    Pascolizumab (SB 240683) is a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.

  3. Drug

    G17DT Immunogen

    go.drugbank.com/drugs/DB04914
    Investigational

    It is also in a phase II/III trial for advanced stomach cancer in combination with 5-fluorouracil and cisplatin and in a late phase II trial for advanced colorectal cancer in combination with irinotecan … It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine.

    Synonyms: G17DT (AN ANTIGASTRIN IMMUNOGEN)
  4. Drug

    Difluprednate

    go.drugbank.com/drugs/DB06781
    ApprovedInvestigational

    Difluprednate is abbreviated DFBA, or difluoroprednisolone butyrate acetate. It is indicated for treatment of endogenous anterior uveiti. … Difluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate.

  5. Drug

    GEM-231

    go.drugbank.com/drugs/DB05798
    Investigational

    A monoclonal antibody combined with a toxic substance that is used treat certain types of acute myeloid leukemia in older patients and is being studied in the treatment of other types of cancer. … Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells.

  6. Drug

    SGX-523

    go.drugbank.com/drugs/DB06314
    Investigational

    A MET receptor tyrosine kinase inhibitor.

  7. Drug

    Dilmapimod

    go.drugbank.com/drugs/DB12140
    Investigational

    Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis). … Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}

  8. Drug

    TAK-475

    go.drugbank.com/drugs/DB05317
    Investigational

    TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.

  9. Drug

    Lanoteplase

    go.drugbank.com/drugs/DB06245
    Experimental

  10. Drug

    Ximelagatran

    go.drugbank.com/drugs/DB04898
    ApprovedWithdrawn

    In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries … Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former.

    Synonyms: ethyl 2-[[(1R)-1-cyclohexyl-2- [(2S)-2-[[4-(N'-hydroxycarbamimidoyl) phenyl]methylcarbamoyl]azetidin-1-yl]- 2-oxo-ethyl]amino]acetate